Roman Fabbricatore

A minimally invasive cryoablation technology system designed to treat patients with kidney tumors and elicit an 89.65% recurrence-free rate.

Findings from a retrospective study showed that outpatient robotic hepatectomies resulted in no mortalities across 307 procedures.

Four trajectories of change were identified in FACT-PWB score, with large patient groups experiencing little to no change or slight declines in PWB.

A trial for BNT326/YL202 in EGFR-mutated NSCLC or HR-positive HER2-negative breast cancer has paused enrollment due to a large illness or injury risk.

Data from the phase 3 PALOMA study showed subcutaneous amivantamab had comparable ORR to intravenous administration for patients with EGFR-mutated NSCLC.

UGN-102 also demonstrated a 79.6% complete response rate at 3 months in the phase 3 ENVISION trial.

Patients with hormone receptor-positive breast cancer experienced weight loss when given a plant-based diet plus exercise.

Phase 2a data show no dose-limiting toxicities with SLS009 among patients with relapsed/refractory acute myeloid leukemia.